# KEYNOTE-921 (NCT03834506)

> Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03834506
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Prostatic Neoplasms
- Interventions: Pembrolizumab; Docetaxel; Prednisone; Placebo; Dexamethasone
- Enrollment: 1030
- Primary outcome: Overall Survival (OS)
- Primary outcome: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on KEYNOTE-921 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-921-nct03834506

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03834506", "email": "<work email>"}; the inbox owner confirms by the emailed link.